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Summary: 
1 5-hydroxytryptamine (5-HT) has been postulated to play a pro-arrhythmic role in the human 
atria via stimulation of 5-HT4 receptors.  
2 The aims of this study were to examine the effects of 5-HT on the L-type Ca
2+
 current (ICaL) 
action potential duration, the effective refractory period (ERP) and arrhythmic activity in human 
atrial cells, and to assess the effects of prior treatment with β-adrenoceptor antagonists. 
3 Isolated myocytes, from the right atrial appendage of 27 consenting patients undergoing 
cardiac surgery who were in sinus rhythm, were studied using the whole cell perforated patch 
clamp technique at 37
o
C.  
4 5-HT (1 nM-10 µM) caused a concentration dependent increase in ICaL, that was potentiated in 
cells from β-blocked (maximum response to 5-HT, Emax=299±12% increase above control) 
compared to non-β-blocked patients (Emax=220±6%, P<0.05), but with no change in either the 
potency (log EC50: -7.09±0.07 vs -7.26±0.06) or Hill coefficient (nH: 1.5±0.6 vs 1.5±0.3) of the 
5-HT concentration-response curve. 
5 5-HT (10 µM) produced a greater increase in the action potential duration at 50% 
repolarisation (APD50) in cells from β-blocked patients (of 37±10 ms, ie: 589±197%) vs non-β-
blocked patients (of 10±4 ms, ie: 157±54%; P<0.05). Both the APD90 and the ERP were 
unaffected by 5-HT.  
6 Arrhythmic activity was observed in response to 5-HT in 5 of 17 cells (29%) studied from β-
blocked, compared to 0 of 16 cells from the non-β-blocked patients (P<0.05).  
7 In summary, the 5-HT-induced increase in calcium current was associated with a prolonged 
early plateau phase of repolarisation, but not late repolarisation or refractoriness, and the 
enhancement of these effects by chronic β-adrenoceptor blockade was associated with 
arrhythmic potential. 
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Introduction 
 5-hydroxytryptamine (5-HT) exerts a variety of effects in the heart, brain, adrenocortical 
cells, urinary bladder and alimentary canal via stimulation of the 5-HT4 receptor sub-type 
(Hegde & Eglen, 1996). The 5-HT4 receptor is functionally present in the human atrium 
(Blondel et al., 1997) but not in the ventricle (Jahnel et al., 1992), which has stimulated interest 
in its possible roles in the occurrence of atrial arrhythmia. It has been postulated that 5-HT is 
involved in the progression of atrial fibrillation (AF) in patients due to its release from 
aggregating platelets within the fibrillating atria (Kaumann, 1994). In addition, there has been 
concern about the potential for atrial arrhythmia generation when using 5-HT4 receptor agonists 
as gastrokinetic agents (Medhurst & Kaumann, 1993; Tonini et al., 1999). In human atrial 
isolated muscle, arrhythmic contractions were induced by 5-HT, and abolished by a selective 5-
HT4 receptor antagonist (Kaumann & Sanders, 1994). 5-HT has been shown to increase the 
magnitude of the L-type calcium current (ICaL) in human atrial myocytes (Jahnel et al., 1993; 
Ouadid et al., 1992), which may contribute to intracellular calcium overload and arrhythmic 
activity. However, in a study of a pig model of atrial flutter/AF (Rahme et al., 1999), the 5-HT4 
receptor antagonist, RS-100302, was demonstrated to be anti-arrhythmic, associated with 
prolongation of the atrial effective refractory period (ERP). This suggested that 5-HT may 
shorten the atrial ERP, which may predispose to AF by reducing the minimum pathlength 
required for re-entry. The importance of these potential arrhythmogenic effects of 5-HT, namely 
calcium overload and/or shortened refractoriness, have not yet been clarified in human atria. 
 One factor that may influence the arrhythmogenic potential of 5-HT is the prior treatment 
of the patient with β-adrenoceptor antagonists. The ability of 5-HT to cause rate-dependent 
arrhythmic contractions in strips of human atrial tissue was facilitated by chronic β-blockade 
(Kaumann & Sanders, 1994; Sanders et al., 1995). In addition, prior β-blocker treatment 
increased the positive inotropic response of human atrial muscle to 5-HT (Sanders et al., 1995; 
Wangemann et al., 2003), but the influence of β-blockade on the effects of 5-HT on ICaL is 
unknown. We have recently reported that chronic β-blockade is associated with prolongation of 
the basal action potential duration (APD) and ERP in human atrial myocytes, and that this effect 
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is not related to a change in ICaL (Workman et al., 2003). Such an increase in APD may result in 
increased contractile tension independent of ICaL (Bers, 2002), and this may underlie the 
increased basal force of contraction in atrial strips from patients pre-treated with β1-
adrenoceptor antagonists (Wangemann et al., 2003). However, the ionic mechanism by which 
chronic β-blockade enhances the effects of 5-HT on human atria, and in particular whether ICaL 
is involved, has not been proven.  
 The aims of this work were: 1) to study how the increase in ICaL by 5-HT may affect the 
action potential morphology, the cellular refractoriness and the occurrence of arrhythmic 
activity, and 2) to investigate the influence of chronic β-blocker therapy on the actions of 5-HT 
on ICaL, APD, ERP and arrhythmic mechanism in human atrial single myocytes. 
 6 
Methods 
 
Tissue and cell isolation 
The procedures for the removal of human tissue were approved by the institutional 
research ethics committee of Glasgow Royal Infirmary, and each patient’s informed consent 
was obtained. The investigation conforms to the principles outlined in the Declaration of 
Helsinki (World Medical Association, 1997). Specimens of the right atrial appendage were 
obtained from patients undergoing cardiac surgery. The excised tissue (weight: 0.45±0.06 g) 
was placed in Tyrode’s solution and transported to the laboratory for processing within 5 min of 
removal. Atrial cells were isolated by enzymatic dissociation and mechanical disaggregation, 
using a modification of the chunk method, described in detail by Workman et al. (2001). 
 
Electrical recording techniques 
 Action potentials and ion currents were recorded using the whole cell patch clamp 
technique, with an Axopatch-1D amplifier (Axon Instruments). Cells were superfused at 37
o
C at 
1.5 ml min
-1
 (RC-24E fast exchange perfusion chamber, Warner) with a physiological salt 
solution containing (mM): NaCl (130.0), KCl (4.0), CaCl2 (2.0), MgCl2 (1.0), glucose (10.0), 
HEPES (10.0), pH 7.4. The perforated patch clamp technique, with nystatin (184 µM), was used 
to prevent cell dialysis, prolonging recording and minimising current “run-down”. 
Microelectrodes were constructed from thin walled, filamented borosilicate glass (Clark 
Electromedical) using a micropipette puller (Narishige PP-83), and heat polished to resistances 
of 3-9 MΩ. To record calcium currents, electrodes were filled with a caesium-based solution (to 
eliminate outward K
+
 currents) containing (mM): CsCl (30.0), HEPES (5.0), MgCl2 (1.0), Cs 
methanesulfonic acid (100.0), NaCl (5.0). To record action potentials, an internal potassium-
based solution was used, containing (mM): KCl (30.0), HEPES (5.0), MgCl2 (1.0), K 
methanesulfonic acid (100.0), NaCl (5.0). Using these solutions, a liquid junction potential of 
+5.0±0.2 mV (n=6) was measured (bath relative to pipette) and was compensated for prior to 
seal formation (Neher, 1992). Only single, elongated myocytes were selected for electrical 
recording. Following seal formation, a gradual reduction in the series resistance due to nystatin 
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pore formation was observed, which stabilised (after ~10 min) at 11.1±0.5 MΩ (n=84 cells). 
The mean cell capacity was 77±3 pF. Capacitative transients were subtracted electronically 
from the recordings. The voltage drop across the series resistance was routinely compensated 
for electronically, by 68-80%. The software program WinWCP (J. Dempster, Strathclyde 
University) was used both to stimulate and record electrical activity. All currents were 
normalized to the cell’s capacity. Current and voltage signals were low pass filtered at 5 kHz 
and digitised (Digidata 1200 A-D converter, Axon Instruments) prior to storage on magnetic 
and compact discs. 
 
Experimental protocols 
 ICaL was recorded under voltage clamp conditions. The voltage-dependency of this 
current was measured from a holding potential of -40 mV with depolarising pulses of 100 ms 
duration (0.33 Hz), increasing in steps of 10 mV, up to +40 mV. The time course of change in 
ICaL due to drugs was examined with repetitive voltage pulses, from -40 to +10 mV.  
Actions potentials were stimulated at 75 beats min
-1
 (bpm) using 5 ms current pulses of 
1.2x threshold strength, after current clamping resting cells at -75 to -80 mV, and keeping the 
holding current (<150 pA) constant thereafter. The stimulus threshold current amplitude was 
initially determined in each cell by stimulating repetitively with trains of three current pulses (5 
ms duration), the 1
st
 and 2
nd
 being of equal, suprathreshold amplitude, and the 3
rd
 pulse 
increasing progressively (from zero, in steps of 50 pA) until it produced a regenerative action 
potential. The stimulus strength was then kept constant throughout all recording protocols in 
each cell. The cell’s ERP was measured using a standard S1-S2 stimulation protocol, with an 8-
pulse conditioning train delivered at 75 bpm, and with S1 and S2 pulses of equal magnitude. The 
S1-S2 interval was shortened in 10 ms steps, and the ERP was defined as the longest S1-S2 
interval which failed to elicit an S2 action potential of amplitude >80% of the preceding S1 
action potential. The APD was calculated as the interval between the action potential upstroke 
and repolarisation to the level of 50% (APD50) and 90% (APD90) of the upstroke amplitude. ICaL 
and/or action potentials and the ERP were recorded before, and 90 s after, drug additions and 
again 180 s after removal of drugs. 
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Drugs 
5-HT (Sigma, St. Louis, Mo., USA) was made up as a 10 mM stock solution in distilled 
water. The specific 5-HT4 antagonist GR-113808 (Kaumann, 1993) was kindly donated by 
Johnson & Johnson Pharmaceutical Research & Development and was prepared as a 10 mM 
stock solution in dimethyl sulfoxide.  
 
Data analysis and statistics 
Details of each patient’s clinical characteristics and drug treatments were obtained from 
the case notes. The cardiac rhythm and heart rate were assessed from the pre-operative 
electrocardiogram. Only those patients in sinus rhythm at the time of surgery were included. 
Cells were excluded from analysis if either the APD50 or peak ICaL decreased irreversibly during 
the protocol. Concentration-response data for the effect of 5-HT on ICaL were fitted iteratively 
(Prism software, Graphpad) with variable slope sigmoidal concentration-response curves, using 
the Hill equation: Y=Emin+[Emax-Emin]/[1+(x/EC50)
nH
], where Y=ICaL density (pA/pF, expressed 
as % above control), Emin=ICaL at 0 mM 5-HT (set to 0%), Emax=maximum ICaL response 
elicitable by 5-HT (% above control), x=[5-HT] (mM), EC50=[5-HT] producing 50% of Emax 
(mM) and nH=Hill coefficient (describing the steepness of the slope). The curves were fitted to 
mean ICaL values, obtained at five concentrations of 5-HT, within the range of 1 nM-10 µM. Use 
of the perforated patch technique maximised the duration of each experiment but it was not 
possible to measure ICaL at every concentration studied in each cell. Curve fit values were 
compared using a two-tailed unpaired Student’s t-test. Measurements taken from the action 
potentials were the resting potential (Vm), overshoot, amplitude and maximum upstroke velocity 
(Vmax), the APD50 and APD90, and the ERP. Data are expressed as mean ± standard error of the 
mean (SEM), with n being equal to the number of cells studied. Mean values were compared 
using two-tailed paired or unpaired Student’s t-tests, as appropriate. A Chi-square test (χ2) was 
used to assess the level of significance of differences in the incidences of arrhythmic activity 
between groups. P<0.05 was regarded as statistically significant. 
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Results 
 
Patients’ characteristics  
 The majority of patients were male, underwent coronary artery bypass graft surgery, 
suffered from angina, and had normal left ventricular function (Table 1). Fifty-nine percent of 
the patients were taking β-adrenoceptor blockers, and 59% calcium channel blockers. Of the 
patients taking β-blockers, 50% were also receiving calcium channel blockers. All patients 
undergoing β-blockade were treated for >1 month with cardiac selective β1-adrenoceptor 
antagonists, namely atenolol (69%), bisoprolol (19%) or metoprolol (12%). No patient was 
administered sotalol (which has additional class III anti-arrhythmic activity) except for 1 patient 
who was changed from sotalol to atenolol 1 week prior to surgery. Patients received their 
routine cardiac drugs on the day of surgery. Of the patients treated with calcium channel 
blockers, 44% were receiving diltiazem, a cardiac-acting drug, and the remaining 56% were 
taking dihydropyridines, with mainly vascular actions, namely amlodipine (38%), felodipine 
(12%) and nifedipine (6%). The heart rate was significantly reduced in β-blocked (62±4 bpm, 
n=16) compared to non-β-blocked patients (75±3 bpm, P<0.05; n=11), but was not altered by 
calcium channel blocker therapy (68±6 vs 66±3 bpm, for treated and non-treated patients, 
respectively). 
  
Effects of 5-HT and GR-113808 on the calcium current in human atrial cells 
 5-HT produced a substantial increase in the amplitude of ICaL, as shown by the original 
recordings in Figure 1a, and by the ICaL current density-voltage relationships in Figure 1b. 5-HT 
(10 µM) increased the mean magnitude of peak ICaL (recorded at +10 mV) from -4.7±0.8 to -
11.9±2.2 pA pF-1 (P<0.05, n=7 cells from 6 patients), ie: by approximately 150%. This increase 
in ICaL occurred without any change in the voltage dependency of the current, and was shown to 
be reversible on washout of 5-HT (-3.7±1.4 pA pF-1; n=3 cells, 3 patients) (Figure 1b). 
 The time course of the effect of 5-HT on ICaL and its blockade by the specific 5-HT4 
receptor antagonist, GR-113808, can be seen in Figure 2. 5-HT (0.1 µM) caused a stable 
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increase in ICaL, which was completely antagonised by 0.1 µM GR-113808. The antagonism of 
the 5-HT-induced increase in ICaL by GR-113808 was seen in 3 cells from 3 patients. The effect 
of this antagonist was partially reversible upon its washout (Figure 2). GR-113808 (0.1 µM) had 
no direct effect on basal (unstimulated by 5-HT) ICaL (2 cells from 2 patients). 
 
The concentration-response relationship of the effect of 5-HT on ICaL  
 The effect of 5-HT on ICaL was concentration dependent. Figure 3a shows the 
concentration-response curve of the effect of 5-HT between 1 nM and 10 µM, fitted to the mean 
values obtained at each concentration. The log EC50 calculated from this curve was -7.15±0.05, 
and the Hill coefficient (nH) was 1.37±0.28 (n=17-33 cells, 9-17 patients). The maximum 
response of ICaL to 5-HT (Emax) was observed to occur at around 1 µM 5-HT, with a value of 
267±7%. 
 In Figure 3b, the 5-HT concentration-response data has been sub-divided into those 
obtained from patients with and without prior treatment with β-blockers. The respective log 
EC50 (-7.09±0.07 and -7.26±0.06) and nH (1.5±0.6 and 1.5±0.3) values were not significantly 
different between these patient groups. By contrast, 5-HT caused a significantly greater increase 
in Emax in β-blocked (at 299±12%, n=9-18 cells, 4-11 patients) than in non-β-blocked patients 
(at 220±6%, n=8-15 cells, 5-7 patients; P<0.05) (Figure 3b). There was no significant difference 
in basal ICaL between non-β-blocked (-5.4±0.7 pA pF
-1
, n=30) and β-blocked patients (-4.2±0.3 
pA pF
-1
, n=50). 
 Pre-treatment with calcium channel blockers did not significantly alter the 
concentration-response curves to 5-HT on ICaL. Similarly, basal ICaL was not significantly 
different between cells from patients who had, and those from patients who had not received 
calcium channel blockers, at -4.8±0.6 (n=32) and -4.5±0.4 pA pF-1 (n=48), respectively. 
 
Effect of 5-HT on action potentials and the refractory period 
 Figure 4a shows original action potentials and ERP measurement, from a single human 
atrial myocyte obtained from a patient who had not been treated with a β-blocker. 5-HT (10 
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µM) produced a small, but significant, prolongation in the APD50, but with little effect on the 
plateau amplitude, late repolarisation (APD90) or the ERP. Mean data confirmed these effects of 
5-HT in the cells from non-treated patients (Figure 4b). 5-HT (10 µM) increased the APD50 
from 6±1 to 16±5 ms (P<0.05), an effect which was fully reversible upon washout of 5-HT, but 
there was no significant or reversible effect of 5-HT on the APD90 (193±20 vs 208±24 ms, 
P>0.05) or ERP (178±23 vs 195±23 ms, P>0.05). Other action potential measurements, 
including Vmax (191±14 V s
-1
), overshoot (59±3 mV) and amplitude (139±2 mV), were 
unaffected by 5-HT.  
 Chronic β-blocker treatment was associated with a greater prolongation of the early 
plateau phase of repolarisation by 5-HT than non-treatment. Figure 5a shows action potential 
traces and ERP measurements in a single cell from a β-blocked patient. 5-HT (10 µM) produced 
an elevation in the action potential plateau, with a consequent lengthening in the duration of the 
APD50. Figure 5b shows mean data confirming this effect in the cells from β-blocked patients, 
with a marked and reversible increase in APD50 by 5-HT, from 13±5 to 50±11 ms (P<0.05). 
The mean prolongation in APD50 was 37±10 ms (P<0.05), representing an increase of 
589±197% (P<0.05). This compares with a prolongation in APD50 by 5-HT in the cells from the 
non-β-blocked patients of 10±4 ms (P<0.05), or 157±54% (P<0.05). Both the absolute and 
percentage increase in APD50 by 5-HT were significantly greater in the cells from the patients 
treated with β-blockers, than in those from the non-treated patients (P<0.05 for each). The 5-
HT-induced increase in the APD50 was abolished by the specific 5-HT4 antagonist GR-113808 
(3 cells from 2 patients, one with and one without prior β-blocker treatment), and this effect of 
the antagonist was partially reversible. In cells from β-blocked patients, 5-HT had no significant 
effect on the APD90 (245±24 vs 240±29 ms, P>0.05) or ERP (231±21 vs 225±20 ms, P>0.05), 
nor on the action potential Vmax, overshoot or amplitude. Prior treatment of patients with 
calcium channel blockers had no significant effect on basal APD50, APD90 or ERP, nor on the 
effects of 5-HT on these parameters. There were no significant differences in the capacity of 
cells obtained from patients treated and not treated with either β-blockers or calcium channel 
blockers. 
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Effects of 5-HT on arrhythmic activity in human atrial cells 
 Chronic β-blockade was associated with an increased incidence of 5-HT-induced atrial 
cellular arrhythmic activity. Figure 6 shows an example of such activity, with the induction of 
delayed afterdepolarisations by 10 µM 5-HT, and their abolition following the removal of 5-HT, 
in a cell from a patient treated with a β-blocker. Abnormal depolarisations, including delayed 
afterdepolarisations and early afterdepolarisations were observed in 5 of 17 (29%) of the cells 
obtained from the patients who underwent chronic β-blockade in which action potentials were 
measured. By contrast, abnormal depolarisations were observed not to occur in response to 5-
HT, in any of the 16 cells from the non-β-blocked patients in which action potentials were 
measured (P<0.05, χ2 test). 
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Discussion 
 The present work has demonstrated, for the first time to our knowledge, that the effects of 
5-HT to increase the L-type Ca
2+
 current and to prolong the early plateau phase of action 
potential repolarisation in human atrial myocytes were each potentiated by prior treatment of 
patients with β-blockers, with evidence of arrhythmogenic activity. Since 5-HT had no effect on 
late repolarisation or refractoriness, it would not be expected to contribute to the shortening of 
re-entrant circuits which stabilises AF. It is more likely that 5-HT may contribute to arrhythmia 
genesis, by causing afterdepolarisations via mechanisms involving increased ICaL and cellular 
calcium overload (Levy, 1989).  
 Atrial fibrillation is known to be associated with platelet activation (Kamath et al., 2001), 
and it has been proposed that the consequent release of 5-HT may be involved in the 
progression of the arrhythmia (Kaumann, 1994). The concentration of free 5-HT in human 
whole blood has been reported to range from nanomolar, rising to nearly micromolar, levels 
after activation of platelets (Joseph et al., 1991). The present results confirm that within this 
concentration range 5-HT has important electrophysiological effects on human atrial myocytes. 
The novel finding of a prolongation by 5-HT of the early plateau phase of atrial action potential 
repolarisation, associated with plateau elevation, with no effect on late repolarisation or the 
ERP, is likely due to the observed increase in ICaL. Whilst an involvement of the transient 
outward K
+
 current, ITO, which also contributes to early repolarisation, cannot be excluded, no 
reports of effects of 5-HT on ITO were found. Furthermore, a predominant contribution from ICaL 
is supported by a report that blockade of ICaL by nifedipine, a calcium channel blocker, markedly 
depressed the action potential plateau in human atrial cells, with a relatively small effect on late 
repolarisation and none on the ERP (Workman et al., 2001). The increase in ICaL may contribute 
to the intracellular calcium overload that occurs in AF, which is thought to contribute to 
subsequent electrophysiological changes (Nattel, 1999). The reported reduction in 5-HT4 
receptor mRNA in chronically fibrillating human atria may represent an adaptive response in 
order to reduce calcium entry (Grammer et al., 2001). 
 There has been only one previous, non-quantitative, study of the effect of 5-HT on human 
atrial action potentials, and 5-HT had no effect on action potential morphology but increased 
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tension in muscle strips, and increased ICaL in myocytes (Jahnel et al., 1993). In the present 
study, the majority of cells exhibited characteristic atrial type 3 action potentials (Dawodu et al., 
1996), ie: with a pronounced phase 1, and a plateau below the level of 50% repolarisation, 
making APD50 more susceptible to changes in plateau amplitude, and hence inward currents. 
There are no previous reports of the effects of 5-HT on the ERP in the human atrium. In a pig 
model of AF, the 5-HT4 receptor antagonist, RS-100302, prolonged the ERP and was anti-
arrhythmic (Rahme et al., 1999). If that effect was a consequence of 5-HT4 receptor blockade 
in-vivo it suggested that 5-HT should reduce the ERP, which, by reducing the minimum 
pathlength required for re-entry, would promote AF (Moe, 1962). Whilst this could represent a 
species-specific effect, or an additional direct action of the drug, it is also recognised that 
myocytes isolated by the “chunk” method may lack the delayed rectifier potassium current (Yue 
et al., 1996). Thus, even if 5-HT increased this current in-vivo, shortening of late repolarisation 
and/or the ERP may not be observed in isolated cells. However, the report of an absence of 
effect of 5-HT on the action potential in intact human atrial muscle (Jahnel et al., 1993) makes 
this less likely, since ERP in human atrial myocytes is closely related to APD90 (Workman et 
al., 2001). 
 The concentration dependent increase in ICaL, mediated via the 5-HT4 receptor sub-type in 
the present report, with an EC50 of about 70 nM, is consistent with that reported for ICaL in 
human atrial myocytes (Ouadid et al., 1992) but is also of a similar potency to that reported for 
the positive inotropic effect of 5-HT in human atrial preparations (Jahnel et al., 1992). The 
present, novel observation of potentiation by β-blockade of the 5-HT effect on ICaL supports the 
likelihood that the reported positive inotropic action of 5-HT, which was also increased by β-
blockade, is directly related to the increase in ICaL. Our finding of an increased efficacy, and no 
change in the EC50, of the effect of 5-HT on ICaL with β-blockade is in agreement with the 
increased maximal inotropic effect of 5-HT in human atrial strips, without change in potency, 
reported by Sanders et al. (1995). This differs from data on cell shortening in the same study 
(increased potency, no increase in maximal response), but is supported by a recent report of 
sensitisation by β-blockade of inotropic responses to 5-HT in human atrial strips (Wangemann 
et al., 2003). The reason for the discrepancy within the study of Sanders et al. (1995), and with 
 15 
our results is unknown, but it suggests that the potentiation of the effect of 5-HT on ICaL is 
correlated better with the maximal inotropic response than with myocyte shortening. 
 Chronic β-blockade has recently been shown to increase basal APD90 and ERP in human 
atrial myocytes, consistent with the trends in the present data, and this “pharmacological 
remodelling” was independent of an effect on ICaL (Workman et al., 2003). By contrast, the 
present effects of β-blockade, on responses to 5-HT, appear more likely to be related to changes 
in the phosphorylation state of the calcium channel. This may be due to intracellular cross-talk 
between Gs-coupled receptor populations, since chronic β-adrenoceptor blockade enhances 
inotropic effects mediated by β2-adrenoceptors, histamine H2 and 5-HT4 stimulation 
(Wangemann et al., 2003). It has been shown that the levels of mRNA encoding human atrial 5-
HT4 receptors were unaffected by chronic β-blockade (Grammer et al., 2001) and the affinity of 
the β2-adrenoceptor was also unaffected (Hall et al., 1990). Thus, the increased efficacy of 5-HT 
with β-blockade that we, and others, have found is likely due to an enhancement of the 
intracellular biochemical cascade which links the receptor to calcium channels, rather than to 
changes in 5-HT4 receptor density or affinity. An alteration in the activity of G-proteins may be 
involved (Grimm et al., 1998; Wang et al., 1999) and whilst expression of atrial Gs and Gi was 
unaffected by chronic β-blockade (Jia et al., 1995), the activity of Gs was enhanced (Wang et 
al., 1999). Furthermore, 5-HT-induced increases in adenylyl cyclase activity (Wangemann et 
al., 2003) and intracellular cAMP (Jahnel et al., 1993), leading to channel phosphorylation and 
increased ICaL availability, are potentiated in atrial tissue from β-blocked patients. 
 In conclusion, these data indicate that, in the human atrium, the 5-HT-induced increase in 
calcium current is associated with a prolonged early plateau phase of repolarisation, but not late 
repolarisation or refractoriness, and that the enhancement of these effects by chronic β-
adrenoceptor blockade is associated with arrhythmic potential. They provide further support for 
the hypothesis that 5-HT released by aggregating platelets during AF, or 5-HT4 receptor 
agonists as therapeutic agents, may contribute to the origin and maintenance of atrial 
arrhythmia.  
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Table 1 
 
 
 n % 
Patients 
Male/female 
27 
21/6 
 
78/22 
Age 66±2  
Surgery:   
CABG 22 82 
CABG+AVR 5 18 
Drugs:   
Ca
2+
 channel blocker 16 59 
ß-blocker 16 59 
ACE inhibitor 14 52 
Nitrate 18 67 
Diuretic 6 22 
Lipid lowering 22 81 
Digoxin 0 0 
Warfarin 0 0 
Symptoms:   
Angina 25 93 
Palpitations 5 19 
Hypertension 15 56 
Hyperlipidaemia 21 78 
Previous History:   
MI 10 37 
Diabetes 2 7 
LV Function:   
-normal 21 78 
-mild-moderate 5 18 
-severe 1 4 
Patients’ pre-operative clinical characteristics 
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Table and Figure legends 
 
Table 1. Patients’ characteristics. 
Values are numbers of patients (n and % of total, respectively) with selected clinical 
characteristics, except for age (mean±SEM). CABG=coronary artery bypass graft surgery, 
AVR=aortic valve replacement, ACE=angiotensin converting enzyme, MI=myocardial 
infarction, LV=left ventricular. All patients were in sinus rhythm at surgery. 
 
Figure 1. 
Effect of 5-HT on ICaL current-voltage relationship in human atrial myocytes. 
Fig. 1a. An example of original calcium current (ICaL) traces obtained from a human atrial cell 
(in this case from a β-blocked patient), during depolarising voltage clamp pulses (100 ms, 0.33 
Hz) from -40 mV to +40 mV, in 10 mV incremental steps, from a holding potential of -40 mV, 
under control conditions (open circle) and in the presence of 5-HT at 10 µM (closed circle). 
Fig. 1b. Current-voltage relationships of ICaL expressed in terms of current density, pA pF
-1
 (n=7 
cells, from 6 patients, treated and not treated with β-blockers). Values are means, with error bars 
denoting SEM, for control (open circles) 5-HT at 10 µM (closed circles) and after 3 min 
washout of 5-HT (open squares, n=3 cells, 3 patients). Asterisks indicate P<0.05 between 
control and 5-HT values at each voltage step (paired t-test). 
 
Figure 2. 
Effect of the specific 5-HT4 antagonist GR-113808 on ICaL stimulated by 5-HT in human atrial 
myocytes. 
An example of the time course of change in peak ICaL density (measured in this case in a cell 
from a β-blocked patient) plotted at 5 s resolution, in response to 0.001 to 0.1 µM 5-HT (open 
boxes), followed by the application of GR-113808 at 0.1 µM (solid box), and the subsequent 
washout of the antagonist and then of 5-HT. Inset traces show original currents recorded at the 
time points labelled. 
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Figure 3. 
Concentration-dependent effects of 5-HT on ICaL in human atrial myocytes.  
Fig. 3a. Concentration-response relationship for 5-HT (0.001-10 µM) on peak ICaL in human 
atrial myocytes. Values are means ±SEM (n=17-33 cells, 9-17 patients). The increase in ICaL is 
expressed as a percentage of the control value before the addition of 5-HT. Mean data points 
were fitted by a variable slope sigmoidal curve using the Hill equation (see Methods). 
Fig. 3b. Comparison of concentration-response curves for 5-HT on ICaL and (inset) of maximal 
ICaL response to 5-HT, Emax, between cells from patients not treated with β-blockers (open 
symbols; n=8-15 cells, 5-7 patients) and those from patients treated with β-blockers (closed 
symbols; n=9-18 cells, 4-11 patients). Asterisk denotes P<0.05 vs non-β-blocked group.  
 
Figure 4. 
Effect of 5-HT on action potentials and refractoriness in single human atrial cells from patients 
not treated with β-blockers. 
Fig. 4a. Representative examples of original action potential recordings obtained from a single 
human atrial myocyte, from a patient not treated with a β-blocker, before (upper panel) and in 
the presence of 10 µM 5-HT (lower panel). Cells were paced at 75 bpm. Dotted lines in bold 
show the level of 50% of the action potential amplitude. The majority of cells displayed type 3 
action potentials, ie: with pronounced phase 1 and a plateau amplitude below the 50% level. The 
effective refractory period (ERP), indicated by solid bars, was calculated as the longest S1-S2 
interval failing to elicit an S2 response of amplitude >80% of the preceding S1 action potential. 
The S2 response used to measure this interval is labelled with an arrow. 
Fig. 4b. Mean (±SEM) action potential duration (ms) measured at 50 and 90% repolarisation 
(APD50 and APD90, respectively; n=16 cells, 8 patients) and ERP (n=12 cells, 8 patients) in cells 
from patients not treated with β-blockers, in the absence (open bars), in the presence (closed 
bars) and after removal of 10 µM 5-HT (striped bars; n=11 cells, 8 patients for APD and n=9 
cells, 7 patients for ERP). Asterisk denotes P<0.05 between control and 5-HT values (paired t-
test).  
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Figure 5 
Effect of 5-HT on action potential duration and refractoriness in human atrial cells from 
patients treated with β-blockers. 
Fig. 5a. Representative examples of action potentials recorded from a single human atrial 
myocyte from a patient treated with a β-blocker, before (upper panel) and in the presence of 5-
HT at 10 µM (lower panel). Cells were paced at 75 bpm. Dotted lines in bold show the level of 
50% of the action potential amplitude. The effective refractory period (ERP), indicated by solid 
bars, was defined and calculated as in the legend of Fig. 4a. 
Fig. 5b. Mean (±SEM) action potential duration (APD50 and APD90; n=17 cells, 9 patients) and 
ERP (n=12 cells, 9 patients) in cells from patients treated with β-blockers, in the absence (open 
bars), in the presence (closed bars) and after removal of 10 µM 5-HT (striped bars; n=7 cells, 5 
patients for APD and n=3 cells, 3 patients for ERP). The asterisk denotes P<0.05 between 
control and 5-HT values (paired t-test). 
 
Figure 6. 
Effect of 5-HT to promote abnormal depolarisations in cells from β-blocked patients. 
An example of original recordings of action potentials obtained from a single human atrial 
myocyte (75 bpm pacing) from a patient treated with a β-blocker, before (top panel), in the 
presence of 5-HT at 10 µM (middle panel), and then following washout of 5-HT (bottom panel). 
The arrow indicates the presence of abnormal depolarisations, which occurred only in the 
presence of 5-HT. 
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Figure 2 
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Figure 3 
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Figure 5 
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Figure 6 
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